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Malignant Transformation of DMBA/TPA-Induced
Papillomas and Nevi in the Skin of Mice Selectively
Lacking Retinoid-X-Receptor a in Epidermal
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Arup Kumar Indra1,6, Eduardo Castaneda1,7, Maria Cristina Antal1,, Ming Jiang1, Nadia Messaddeq1,
Xiangjun Meng1, Christiane V. Loehr2, Patricio Gariglio3, Shigeaki Kato4, Walter Wahli5,
Be´atrice Desvergne5, Daniel Metzger1 and Pierre Chambon1
Retinoid-X-receptor a (RXRa), a member of the nuclear receptor (NR) superfamily, is a ligand-dependent
transcriptional regulatory factor. It plays a crucial role in NR signalling through heterodimerization with some 15
NRs. We investigated the role of RXRa and its partners on mouse skin tumor formation and malignant
progression upon topical DMBA/TPA treatment. In mutants selectively ablated for RXRa in keratinocytes,
epidermal tumors increased in size and number, and frequently progressed to carcinomas. As keratinocyte-
selective peroxisome proliferator-activated receptor gamma (PPARg) ablation had similar effects, RXRa/PPARg
heterodimers most probably mediate epidermal tumor suppression. Keratinocyte-selective RXRa-null and
vitamin-D-receptor null mice also exhibited more numerous dermal melanocytic growths (nevi) than control
mice, but only nevi from RXRa mutant mice progressed to invasive human-melanoma-like tumors. Distinct
RXRa-mediated molecular events appear therefore to be involved, in keratinocytes, in cell-autonomous
suppression of epidermal tumorigenesis and malignant progression, and in non-cell-autonomous suppression
of nevi formation and progression. Our study emphasizes the crucial role of keratinocytes in chemically
induced epidermal and melanocytic tumorigenesis, and raises the possibility that they could play a similar role
in UV-induced tumorigenesis, notably in nevi formation and progression to melanoma.
Journal of Investigative Dermatology (2007) 127, 1250–1260. doi:10.1038/sj.jid.5700672; published online 15 February 2007
INTRODUCTION
Retinoids (principally all-trans retinoic acid, the active vitamin
A derivative) are involved in control (CT) of growth and
differentiation of normal, premalignant, and malignant cell
types (Altucci and Gronemeyer, 2001). Their effects are
mediated through binding to members of two families of
nuclear receptors (NRs), the retinoic acid (RA) (RARa, b, and
g), and retinoid X (RXRa, b, and g) receptors, usually associated
as heterodimers (Mangelsdorf et al., 1995; Chambon, 1996;
and reference therein). Vitamin A deficiency in humans and
animal models results in epithelial squamous metaplasia prone
to malignant conversion (Hong and Itri, 1994; Moon et al.,
1994), whereas natural and synthetic retinoids are used for
treatment of skin disorders including psoriasis and acnea
(Livrea, 2000), and as chemopreventive agents for epidermal
cancers (Altucci and Gronemeyer, 2001; Sun and Lotan,
2002). Altered expression of RARs and RXRs during carcino-
genesis may reduce the ability of epidermal cell to respond to
RA, and contribute to carcinoma development, both in mice
(Darwiche et al., 1995; Darwiche et al., 1996) and humans
(Sun and Lotan, 2002). In mice, dietary RA prevents tumor
formation and malignant conversion of chemically induced
skin papillomas (De Luca et al., 1996, and references therein;
Tennenbaum et al., 1998).
The two-step chemical tumorigenesis model has been
widely used to study initiation, promotion, and progression
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(malignant conversion) of mouse skin tumors, as the
evolution of human squamous cell carcinoma (SCC) has
many similarities with mouse chemically induced squamous
cell tumors (Yuspa, 1998, and references therein).
The initiation stage is achieved through a single topical
appplication of 7,12-dimethyl-benz[a]anthracene (DMBA).
Promotion is accomplished by repeated topical application of
a tumor promoter (i.e., phorbol ester 12-O-tetradecanoyl-
phorbol-13 acetate (TPA)), which causes a sustained hyper-
plasia and inflammation, and then a selective clonal
expansion into benign papillomas (Yuspa, 1998, and
references therein). The third stage, progression, is the
malignant conversion of benign papillomas to invasive
SCC. Cutaneous papillomas and SCCs induced by DMBA/
TPA treatment, as well as human SCC, have been shown to
contain the Ha-ras gene codon 61 (A182-T) mutation
(Nelson et al., 1992, and references therein), and deletion
of Ha-ras drastically decreases the incidence of DMBA/TPA-
induced papillomas (Ise et al., 2000). Interestingly, benign
melanocytic dermal tumors (nevi) are induced in mouse skin
upon a single topical DMBA application. However, these
nevi in which N-ras, but not Ha-ras mutations at codon 61,
have been found, never progress to malignant melanomas
(Husain et al., 1991).
RXRa, RXRb, RARa, and RARg are expressed in human
and mouse epidermis, and RXRa and RARg are the
predominant receptors (Fisher and Voorhees, 1996; Chapel-
lier et al., 2002). The RXRa-null mutation is lethal in utero
between gestation days 13.5 and 16.5 (Kastner et al., 1994;
Sucov et al., 1994), precluding genetic studies of its
physiological function in skin homeostasis. This became
possible through conditional inactivation of RXRa using
the Cre/loxP technology, and transgenic mice selectively
expressing the tamoxifen (TAM)-inducible Cre-ERT2 recom-
binase in epidermal keratinocytes (Li et al., 2000; Metzger
et al., 2003). RXRa ablation in keratinocytes of adult
mice resulted in alopecia, epidermal keratinocyte hyperpro-
liferation, and aberrant terminal differentiation, and skin
inflammatory reaction (Li et al., 2000, 2001). In addition to
RARs, RXRs are also known to heterodimerize with other
members of the NR superfamily (e.g., peroxisome prolifera-
tor-activated receptors (PPARs), vitamin-D-receptor (VDR),
and liver-X-receptors (LXRs); (Laudet and Gronemeyer,
2002)) expressed in the epidermis (Li et al., 2000; Fowler
et al., 2003; Mao-Qiang et al., 2004; Schmuth et al., 2004,
and references therein; Sheu et al., 2002). Ligands of PPARs
and VDR have been shown to inhibit the growth of SCC cell
lines in vitro and multistage skin tumorigenesis in vivo
(Kensler et al., 2000; Kopelovich et al., 2002; Nikitakis et al.,
2002), and those of LXRs display anti-inflammatory activity
against TPA-induced cutaneous inflammation (Fowler et al.,
2003). Thus, RXR(s) and in particular RXRa, could be
critical in transducing cellular signals controlling skin
carcinogenesis.
To investigate the possible role of RXRa in papilloma
formation and their malignant conversion, as well as in
melanocytic growth (MG) formation and progression to
melanoma, we have subjected adult mice selectively ablated
for RXRa in keratinocytes, to chemical two-step tumorigen-
esis. Upon DMBA/TPA treatment they exhibited an increased
number of epidermal tumors, which were also bigger and
progressed with a much higher frequency to malignant
carcinoma, thus establishing a cell-autonomous role of RXRa
in epidermal tumor suppression. These DMBA/TPA-treated
mutants also developed MGs degenerating into invasive
human melanoma-like MGs, which appear to be induced by
paracrine signal(s) emanating from RXRa-ablated epidermal
keratinocytes. We also investigated the role of several NRs as
possible partners of RXRa in these tumor suppressions.
RESULTS
Keratinocyte-selective ablation of RXRa increases the formation
and growth of epidermal tumors in DMBA/TPA-treated mice
RXRaep/ (epidermal keratinocyte-selective RXRaL/L-null
genotype) mice, as well as CT RXRaep/þ and RXRaL2/L2 mice
carrying either one RXRa L null allele and one wild-type
allele selectively in keratinocytes or two floxed RXRa L2
alleles, were generated by Tam treatment of K14-Cre-ERT2/
RXRaL2/L2, K14-Cre-ERT2/RXRaL2/þ , and RXRaL2/L2 litter-
mates, respectively (Materials and Methods; Li et al., 2000;
Metzger et al., 2003). All CT and RXRaep/ mice were on a
similar mixed genetic background (see Materials and
Methods). CT and RXRaep/ female mice were topically
treated, 2 weeks after Tam administration, with DMBA, and
then twice a week with TPA for 25–30 weeks (RXRaep/(a)
mice, see Figure 1a, and Materials and Methods). After 7–8
weeks epidermal tumors developed in all mice. Their number
and size increased with time (Figure 1b, and data not shown),
but they were more numerous and bigger in RXRaep/(a)
mice (Figure 1b–d, and data not shown). The number of
tumors was 2-fold lower in CT males, but RXRaep/(a) males
also exhibited twice as many tumors as CT littermates, and
their size was also increased (not shown). All further work
was performed on females. In all cases, DMBA initiation was
required to generate these tumors, as none appeared with
TPA alone (not shown).
To investigate whether RXRa was involved in tumor
initiation and/or promotion, mice were DMBA-treated, and
then with TPA, for 7 weeks before Tam-induced RXRa
ablation (RXRaep/(b) mice, Figure 1a). Tumors appeared
after 6–7 weeks of TPA treatment in CT and RXRaep/(b)
mice, and by 30 weeks the latter had twice as many tumors as
CT mice (Figure 1e and f, and data not shown). Thus, the lack
of RXRa did not affect tumor initiation, whereas it enhanced
tumor promotion. Accordingly, the H-ras codon 61 ‘‘activat-
ing’’ mutation (see Introduction) was similarly present in CT
and RXRaep/ tumors (not shown).
Epidermal tumors generated in RXRaep/ mice have a ‘‘high
risk’’ of malignant conversion
Changes in keratin expression during DMBA/TPA tumorigen-
esis are used to classify papillomas into ‘‘high’’ and ‘‘low’’
risk for malignant progression. Loss of keratins K1 and K10
expressed in suprabasal layers of normal epidermis and in
‘‘low risk’’ papillomas, and the concomitant appearance of
K13, normally not expressed in epidermis, are indicators of
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early stages of malignant conversion (Nischt et al., 1988, and
references therein; Rundhaug et al., 1997). Immunohisto-
chemistry of tumors (8–16 mm in length) taken 22 weeks after
the start of DMBA/TPA treatment was performed using keratin
K5, K1, K10, and K13 antibodies (Figure 2a). K5, ‘‘normally’’
selectively expressed in basal cell layer persisted throughout
suprabasal layers of highly stratified tumors from CT and
RXRaep/(a) mice, but higher K5 levels were found in
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Figure 1. DMBA/TPA-induced epidermal tumors and MGs in RXRaep/ mice. (a) Timing of Tam-induced RXRa ablation in epidermal keratinocytes, and
DMBA/TPA-induced tumorigenesis. Tam-treatment was started either 18 days before (‘‘a’’) or 8 weeks after (‘‘b’’) topical DMBA application. (b) Formation of
epidermal tumors in DMBA/TPA-treated CT (K14-Cre-ERT2(0/0)/RXRaL2/L2) and RXRaep/(a) mice. (c) Dorsal view of CT (left) and RXRaep/(a) (right) mice
after 25 weeks of DMBA/TPA treatment. (d) Epidermal tumor length distribution in CT and RXRaep/(a) mice, after 30 weeks of DMBA/TPA treatment.
(e) Formation of epidermal tumors in DMBA/TPA-treated CT and RXRaep/(b) mice in which RXRa was ablated in keratinocytes during TPA promotion.
(f) Epidermal tumor length distribution in CT and RXRaep/(b) mice, after 30 weeks of DMBA/TPA treatment. (g) Dorsal view of CT (K14-Cre-ERT2(0/0)/RXRaL2/L2)
(left) and RXRaep/ (right) mice 25 weeks after DMBA treatment. Arrows point to MGs. (h) Size distribution of MGs (as indicated), 30 weeks after DMBA
or DMBA/TPA treatments. Values are expressed as mean7SEM (n¼7).
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RXRaep/(a) tumors (Figure 2a and b). K1 and K10, expressed
in suprabasal cell layers of 470% of CT tumors (Figure 2c
and e), were expressed in o25% of RXRaep/(a) tumors
(Figure 2d and f). Tumors expressing K13 were 3–4 times
more frequent in RXRaep/(a) mice, and more than 70% of
the tumor area was stained (15% in CT mice; Figure 2g and h,
and data not shown).
Upregulation of a6 and b4 integrins (normally expressed in
basal cells and mainly found in basement membrane), and
their presence into several cell layers above the basement
membrane, are associated with a high risk of malignant
conversion (Tennenbaum et al., 1993). a6 and b4 Integrin
expression was much stronger in RXRaep/(a) tumors and
extended into suprabasal layers (Figure 2i and j, and not
shown), whereas restricted to the basal layer in 490% of CT
tumors. Furthermore, 70% of RXRaep/(a) tumors exhibited
increased immunostaining of CD31 which labels endothelial
intercellular junctions (Figure 2k and I, and data not shown).
Taken together, these data indicate that DMBA/TPA-induced
tumors exhibit a higher malignant progression in RXRaep/
mice.
DMBA/TPA-induced tumors degenerate at a low rate into
SCC, but not into basal cell carcinoma (Yuspa, 1998, and
references therein) (see Table 1). Nine tumors from each of 6
CT and 6 RXRaep/(a) mice were examined. After 25 weeks
of DMBA/TPA treatment, most of CT tumors were benign
papillomas characterised by skin folds integrated by a core of
connective tissue and lined by an acanthotic, hyperkeratotic,
stratified squamous epithelium (Figure 2m, and data not
shown). 20% of the papillomas exhibited basal cell hyper-
plasia (Figure 2n), 3% displayed in situ carcinoma (not
shown), and foci of early SCC were observed 30 weeks after
tumor initiation in B14% of the tumors (Figure 2o, Table 1,
and not shown). In contrast, 25 weeks after initiation,B30%
of RXRaep/(a) papillomas exhibited basal cell hyperplasia
(Figure 2q), 10% displayed in situ carcinoma (not shown),
and 40% showed foci of SCC (Figure 2r). Five weeks later,
46% of these tumors had progressed to differentiated and
undifferentiated SCC with extensive local invasion into the
dermis and underlying muscles (Figure 2s–v, Table 1, and not
shown). Well-differentiated SCC (Figure 2s), moderately
differentiated SCC (Figure 2t), as well as poorly differentiated
SCC (Figure 2u), were observed in 30–45% of the tumors
(Table 1). Highly aggressive anaplastic SCC (B3%; Figure 2v)
and basal cell carcinoma (B6%;Figure 2w and x) were also
found in RXRaep/(a), but never in CT mice (Table 1).
Generation of invasive human-melanoma-like MGs in skin of
RXRaep/ mice upon DMBA/TPA treatment
A single DMBA application to WT skin induces the formation
of nevi (benign MGs) that become visible after 10–12 weeks,
and are characterized by subepidermal accumulation of
melanocytes (Epstein, 1992 and references therein; Husain
et al., 1991). Interestingly, a single DMBA treatment of
RXRaep/ mice resulted in B7-fold increase in the number
of MGs which were generally larger than those of CT (Figure
1g and h, and not shown). Multiple TPA applications after
DMBA initiation further increased the number of MGs in CT
and mutant mice (Figure 1h; compare also Figure 1c and g,
and not shown). After 30 weeks of DMBA/TPA treatment,
B10 nevi were observed per CT mouse (diameter below
2 mm), whereas 450 MGs were found per RXRaep/(a)
mouse (75% with a diameter over 2 mm and 7% with a
diameter over 4 mm; see Figure 1h, and data not shown).
When RXRa was ablated 8 weeks after DMBA treatment
(Figure 1a), the number of MGs was B3-fold higher in
RXRaep/(b) than in CT mice, and about 40% of them had a
diameter 42 mm (Figure 1h). Thus both MG initiation and
promotion might be increased upon ablation of RXRa.
Histological analysis of DMBA or DMBA/TPA-induced
MGs showed an accumulation of melanocytes in CT dermis,
whereas a larger number of densely melanin-laden melano-
cytes was seen in both RXRaep/ dermis and hypodermis
(Figure 3a and b). Most interestingly, 15–20% of the 2–4 mm
MGs, and B95% of 44 mm MGs from RXRaep/ mice
exhibited a vertical invasion of the underlying musculature
(Figure 3b and data not shown). However, in most cases the
basement membrane of RXRaep/ mice appeared intact and
only few melanocytes (1–2%) were found in both CT and
RXRaep/ epidermis (Figure 3a and b). As previously
reported (Ghadially, 1997), electron microscopy revealed
that melanocytes from CT nevi contained mainly stage III and
IV melanosomes (Figure 3c and e, and not shown). On the
other hand, most of the melanocytes present in RXRaep/
MGs showed a B10-fold increase in melanosomes contain-
ing melanin granules, and their nuclei were more elongated
(Figure 3d and f). Moreover, in B40% of the RXRaep/
melanocytes, 40–50% of the melanosomes had a variable
electron opacity with a distinct substructure, a characteristic
of human melanoma cells (Ghadially, 1997) (Figure 3d and f,
arrows, and not shown). In addition, the membrane of a
number of melanosomes was disrupted and smaller melanin
granules were scattered in the cellular matrix (Figure 3f, and
not shown). In rare cases, oval shaped vesicles contained a
longitudinally oriented component made of rods, which is
characteristic of human melanoma cells (Figure 3g; Gha-
dially, 1997). Taken together, these results indicate the
formation of human melanoma-like MGs in the skin of
RXRaep/ mice. However, we failed to detect in MGs of
either CT or RXRaep/ mice the N-Ras and BRAF mutations
which have been found in human melanoma and nevi (see
Supplementary Material).
To demonstrate that RXRa was not ablated in MGs, PCR
genotyping was performed on DNA isolated from large nevi
of CT and RXRaep/ mice (Materials and Methods). RXRa L2
alleles, but no RXRa L alleles, were found in RXRaep/
melanocytic tumors induced by DMBA or DMBA/TPA,
whereas only L alleles were found in their surrounding
epidermis (Figure 3h). Thus the formation of nevi and
melanomas in DMBA-treated RXRaep/ mice is associated
with RXRa ablation in keratinocytes, but not in melanocytes.
TPA-induced promotion of DMBA-initiated epidermal tumors
can be suppressed by inhibitors of activator protein-1 activity,
such as the synthetic glucocorticoid fluocinolone acetonide
(FA) (Huang et al., 1997). Topical FA application similarly
prevented the appearance of epidermal tumors in 100% of
www.jidonline.org 1253
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Figure 2. Immunohistochemical and histological analyses of skin tumors induced by DMBA/TPA treatment in RXRaep/ mice. (a) Representative sections
of tumor biopsies from (a, c, e, g, i, k) CT and (b, d, f, h, j, l) RXRaep/(a) mice (after 22 weeks of DMBA/TPA treatment), stained with antibodies against (a, b) K5,
(c, d) K1, (e, f) K10, (g, h) K13, (i, j) a6 integrin, and (k, l) CD31. Red corresponds to antibody staining and blue to DNA 40,6-diamidino-2-phenylindole,
dihydrochloride staining. Bar¼25 mm. (m–o) Representative hematoxylin- and eosin-stained 5-mm-thick paraffin sections from CT biopsies taken after (m, n) 25
and (o) 30 weeks of DMBA/TPA treatment. (m) Suprabasal cell hyperplasia (acanthosis) within a benign papilloma; (n) basal cell hyperplasia within a benign
papilloma; (o) focus of early SCC. (p–x) Representative hematoxylin- and eosin-stained 5-mm-thick paraffin sections from RXRaep/ tumor biopsies taken after
(p–r) 25 and (s–x) 30 weeks of DMBA/TPA treatment. (p) suprabasal cell hyperplasia within a benign papilloma; (q) basal cell hyperplasia within a benign
papilloma; (r) focus of early SSC; (s) well differentiated (note keratin pearls (white arrow) with keratinization in the center), (t) moderately differentiated (cells are
markedly irregular in shape and size, and nuclei are hyperchromatic (blue arrowhead) with prominent nucleoli; note internal keratinization (asterisk)), and
(u) poorly differentiated (note pleiomorphic cancer cells with abnormal nuclei and prominent nucleoli) SCC; (v) anaplastic SCC with spindle-shaped cells and
absence (or minimal) keratinization; (w, x) basal cell carcinoma with densely packed basophilic cells with hyperchromatic nuclei resembling those of
epidermal basal cells. Hyperplastic basal (blue brackets) and suprabasal (black brackets) cell layers in (n, q) and (m, n, p, and q) are indicated. Black arrows in
(m, p) point to basal cell layers; white arrow in (s) points to a keratin pearl; black and blue arrowheads in (r and t), point to a mitosis and abnormal nuclei,
respectively; asterisk in (t) indicates internal cell keratinization. Bar in (m) 33 mm for (m, n, p, and q); 22 mm for (o) and (r–x).
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DMBA/TPA-treated CT (K14-Cre-ERT2(0/0)/RXRaL2/L2 mice,
(n¼10)) and RXRaep/ mice (n¼ 15) while, strikingly, it
did not affect the increased generation of MGs and their
malignant progression in RXRaep/ mice when compared to
CT mice (Figure 4, compare with Figure 1c; and data not
shown).
Selective ablation of PPARc in keratinocytes enhances
DMBA/TPA-induced epidermal tumorigenesis
To investigate whether the RXRa tumor suppressive effect
could be due to events controlled by RXRa/PPARg hetero-
dimers, PPARgep/ (for epidermal keratinocyte-selective
PPARg-null genotype) mice, as well as their CT littermates
(PPARgL2/L2, which carry two PPARg L2 floxed alleles (Imai
et al., 2004), were obtained by Tam administration to K14-
Cre-ERT2/PPARgL2/L2 and PPARgL2/L2 littermates, respectively.
Unlike RXRaep/ and VDR/ mice (see Li et al., 2000 and
Figure 1), PPARgep/ mice did not exhibit an alopecia.
Furthermore, in contrast to RXRaep/ mice, PPARgep/ mice
showed only a modest increase in keratinocyte proliferation
6–8 weeks after Tam-induced ablation (E15% when
compared to CT mice, as determined from IHC staining of
the Ki67 proliferation marker; not shown), and did not exhibit
abnormal interfollicular epidermis differentiation, nor skin
inflammatory reaction (Mao-Qiang et al., 2004, and our
unpublished data).
Starting 2 weeks after Tam administration (as in Figure 1a),
CT and PPARgep/(a) female mice were subjected to DMBA/
TPA treatment. All mice developed epidermal tumors, but
their number was 2-fold increased in PPARgep/(a) mice, and
they were generally larger than those of CT (Figure 5a–c). To
investigate whether the effect of PPARg on tumorigenesis was
exerted on initiation and/or promotion steps, PPARg was
selectively ablated by Tam administration 7 weeks after the
start of the DMBA/TPA treatment (PPARgep/(b) mice; as in
Figure 1a). Epidermal tumors appearedB1 week later in both
CT and PPARgep/(b) mice. After 30 weeks, their number was
again approximately 2-fold increased in PPARgep/(b) mice
(Figure 5d and e), indicating that PPARg ablation in epidermal
keratinocytes stimulates the promotion, but not the initiation
step of tumorigenesis. Treatment with TPA alone was not
tumorigenic (not shown). Histological analysis of 40 tumors
from PPARgep/(a) mice, 30 weeks after tumor promotion,
revealed that 68% of these tumors were benign papillomas,
whereas 24.5% had progressed to SCC, and 2.5% to basal
cell carcinoma (Table 1).
MGs also appeared on DMBA/TPA-treated PPARgep/(a)
and PPARgep/(b) mice (not shown). However, their number
was similar in PPARgep/ and CT mice (Figure 5f), and their
analysis (MGsB2 mm in diameter) showed dermal melanin-
laden melanocytes similar to those observed in benign nevi
(see above), with no evidence of malignant progression (not
shown).
DMBA/TPA treatment of VDR-null mutant mice does not
enhance epidermal tumorigenesis, but increases the formation
of MGs
Like RXRaep/ mice, VDR-null (VDR/) mice (Yoshizawa
et al., 1997) develop an alopecia, which suggested that RXRa/
VDR heterodimers are indispensible during hair cycling
(Li et al., 2001, and references therein; Li et al., 2000). It
has also been reported that vitamin D3, the active VDR
ligand, can induce both cell cycle arrest and differentiation in
vitro of human cell lines derived from SCC (Niles, 1995) and
melanoma (Yudoh et al., 1999), and reduce tumor formation
in the two-step chemical tumorigenesis mouse model (Chida
et al., 1985; Kensler et al., 2000). Eight-to-nine-week-old
VDR-null mutant and WT CT females were DMBA/TPA-
treated to investigate whether VDR could be involved in the
tumor-suppressive effect of RXRa. Seven to eight weeks after
the start of TPA treatment, papillomas developed similarly in
all CT and mutant mice (Figure 6a and b, and data not
shown), although they were in general smaller in VDR/
than in CT mice (Figure 6a–c). Histological analysis of 40
tumors, 30 weeks after DMBA initiation revealed that, unlike
RXRaep/ mutants, 95% of the papillomas were benign,
whereas the others only exhibited foci of early SCC (Table 1,
and data not shown).
MGs also appeared on DMBA and DMBA/TPA-treated
skin of VDR/ mice, and their number was strikingly high to
Table 1. Incidence of malignant progression in papillomas generated by a 30-week DMBA/TPA treatment of mice
selectively lacking either RXRa or PPARc in epidermal keratinocytes, or VDR/ null mice
Papillomas Papillomas with SCC
Papillomas
with BCC
Mice Benign
With in situ
carcinoma With FC
Well
differentiated
Moderately
differentiated
Poorly
differentiated
Anaplastic
carcinomas
Control 29/35 (83%) 1/35 (3%) 5/35 (14%) 0/35 0/35 0/35 0/35 0/35
RXRaep/ 11/35 (31%) 1/35 (3%) 4/35 (11%) 11/35 (31%) 3/35 (9%) 2/35 (6%) 1/35 (3%) 2/35 (6%)
PPARgep/ 25/41 (68%) 0/41 2/41 (5%) 7/41 (17%) 0/41 2/41 (5%) 1/41 (2.5%) 1/41 (2.5%)
VDR/ 38/40 (95%) 0/40 2/40 (5%) 0/40 0/40 0/40 0/40 0/40
BCC, basal cell carcinoma; DMBA, 7,12-dimethyl-benz[a]anthracene; FC, foci of early squamous cell carcinoma; PPAR, peroxisome proliferator-activated
receptor; RXR, retinoid-X-receptor; TPA, 12-O-tetradecanoylphorbol-13 acetate.
Epidermal tumors obtained 30 weeks after DMBA/TPA application from six controls, six RXRaep/(a), six PPARgep/(a) and six VDR/ mice were analyzed
and histologically classified, as indicated.
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reachB70 MGs after 30 weeks of TPA application (instead of
B10 MGs in CT mice, Figure 6d). In both cases, histological
analysis of 30 MGs from CT and VDR/ mice showed the
presence of dermal melanin-laden melanocytes (Figure 6e
and f, and data not shown), and electron microscopy
revealed that they contained mostly stage III and stage IV
melanosomes which are characteristics of benign nevi (Figure
6g and h). However, the number of melanosomes was
approximately 2-fold increased inB10% of the melanocytes
present in VDR/ MGs (Figure 6g and h, and data not
shown).
DISCUSSION
Keratinocytic RXRa and PPARc act as tumor modifiers of both
promotion and malignant progression of epidermal tumors
induced by topical DMBA/TPA treatment
Our results show that RXRa acts as a tumor modifier of both
the TPA-induced promotion of benign papilloma-like tumors
and their subsequent progression to malignancy, whereas the
DMBA-induced initiation step which, results in H-ras
activation is not affected. TPA-induced tumor necrosis
factor-a expression in keratinocytes, which results in their
hyperproliferation and a skin inflammation, is known to be
critical for tumor promotion (Moore et al., 1999; Suganuma
et al., 1999), and to be suppressed by inhibitors of activator
protein-1 activity, such as the glucocorticoid FA (Huang
et al., 1997). As keratinocyte hyperproliferation and skin
inflammation are also generated upon RXRa ablation in
epidermal keratinocytes (Li et al., 2000, 2001), and given the
association between chronic inflammation and cancer
(Coussens and Werb, 2002), the question arises whether the
promoting effect of RXRa ablation could correspond to an
increase in tumor necrosis factor-a production. No such
increase was found, ruling out that it could be responsible for
the enhancement of TPA-induced tumor promotion observed
upon RXRa ablation, even though this enhancement was also
suppressed by administration of FA (data not shown).
In quest of partners with which RXRa may heterodimerize
in keratinocytes to modify the TPA-induced promotion and
malignant progression of DMBA-initiated epidermal tumors,
mice ablated for NRs known to be expressed in the skin were
also subjected to the same DMBA/TPA treatment. PPARa
(Sheu et al., 2002), PPARb(d) (Schmuth et al., 2004) and
PPARg (Mao-Qiang et al., 2004) were selected as their
CT CTRXRep–/– RXRep–/– CT RXRep–/–
DMBA/TPA+FA
Figure 4. Effect of FA treatment on DMBA/TPA-induced epidermal tumors and MGs. Dorsal view of three CT (K14-Cre-ERT2(0/0)/RXRaL2/L2 mice) and three
RXRaep/ mice after 25 weeks of DMBA/TPA and FA co-treatment of the shaved area. These mice are representative of 10 CT and 15 RXRaep/ mice.
DMBA DMBA+TPA
CT RXRep–/–
CT RXRep–/–(a)
E MG E E D E E DMGMG
MG MG
Skin
No MG No MG
1 2 3 4 5 6 7 8 9 10
a b
c
e f g h
d
E
D
H
D
E
H
L2
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Figure 3. DMBA/TPA induced human melanoma like MGs in RXRaep/ mice.
(a–g) Histological and ultrastructural analyses of MGs from CT and RXRaep/(a)
mice. (a and b) Hematoxylin and eosin-stained paraffin sections (5mm thick) of
(a) CT (K14-Cre-ERT2(0/0)/RXRaL2/L2) and (b) RXRaep/(a) MG containing skin
biopsies taken 25 weeks after DMBA/TPA treatment. The arrow in (b) points to
melanocytic invasion of the hypodermis. E, epidermis; D, dermis; H,
hypodermis. Bar¼ 33mm. (c–g) Electron microscopic analyses of (c and e) CT
and (d, f, and g) RXRaep/(a) MGs isolated 25 weeks after DMBA/TPA
treatment. Note in the inset (g), the oval-shaped subcellular structure containing
a longitudinally oriented component made of rods. Arrows in (c, d, and f) point
to (c) CT ‘‘normal’’ dermal melanocytes, and (d and f) abnormally shaped
melanosomes typical of human-melanoma-like MG, respectively. Arrowheads
in (c and e) point towards a melanin-laden melanophage and melanosomes of
stage III and IV, respectively. N, nucleus. Bars¼2.5mm for (c and d); 1mm for (e
and f) and 0.25mm for the (g) inset. (h) RXRa is not ablated in MGs from
RXRaep/ mice. The presence of RXRa L2 and L alleles was analysed by PCR
in DNA from epidermis (E), dermis (D), isolated from MG-free skin biopsies
(NoMG) and MG from CT (lanes 1 and 2, K14-Cre-ERT2(0/0)/RXRaL2/L2) and
RXRaep/ (lanes 3–10) mice, 25 weeks after DMBA or DMBA/TPA treatment,
as indicated. The position of the RXRa L2 and L alleles is indicated.
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activator ligands are known to inhibit TPA-induced cuta-
neous inflammation. The selective ablation of PPARb in basal
keratinocytes of adult mouse skin had no significant effect on
DMBA/TPA-induced tumorigenesis (our unpublished data).
As it has been reported that this tumorigenesis is enhanced in
PPARb-null mice (Kim et al., 2004), PPARb might exert its
tumor modifier activity in non-keratinocyte cells, and /or its
expresssion in keratinocytes of the developing epidermis
might prevent tumorigenesis. In contrast, in PPARgep/ mice
ablated for PPARg in keratinocytes, the increased formation
of epidermal tumors and their elevated progression to
carcinomas, were similar to those observed in RXRaep/
mice, even though, in contrast to RXRa, the selective ablation
of PPARg in keratinocytes does not result in skin inflamma-
tion (Mao-Qiang et al., 2004, and our unpublished results).
Thus, PPARg is likely to be the RXRa heterodimerization
partner in the cell-autonomous process(es) that CT(s) tumor
promotion and malignant progression in DMBA/TPA-treated
mice. Interestingly, germ line null mutations of PPARa or
LXRb, whose activations inhibit TPA-induced cutaneous
inflammation (Fowler et al., 2003), similarly resulted in 1.5
to 2-fold increased formation of DMBA/TPA-induced tumors
(our unpublished results). Keratinocyte-selective ablation
PPARa and LXRb is required to determine whether RXRa/
PPARa and RXRa/LXRb heterodimers also act as cell-
autonomous epidermal tumor modifiers. On the other hand,
germline null mutations of VDR (this study), as well as single
or compound RARa and RARg or RARb keratinocyte-selective
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Figure 5. DMBA/TPA-induced epidermal tumors and MGs in PPARcep/(a) and PPARcep/(b) mice. (a) Formation of epidermal tumors in DMBA/TPA-treated
CT and PPARgep/(a) mice. (b) Dorsal view of CT (K14-Cre-ERT2(0/0)/PPARgL2/L2) (left) and PPARgep/(a) (right) mice 25 weeks after the start of DMBA/TPA
treatment. (c) Length distribution of epidermal tumors in CT and PPARgep/(a) mice as measured after 25 weeks of DMBA/TPA treatment. (d) Formation of
epidermal tumors in DMBA/TPA-treated PPARgep/(b) mice in which PPARg was ablated in keratinocytes during TPA promotion. (e) Length distribution of
epidermal tumors in CT and PPARgep/(b) mice, after 25 weeks of TPA treatment. (f) Size distribution (diameter) of MGs in CT, PPARgep/(a), and PPARgep/(b)
mice. Values are expressed as mean7SEM (n¼ 7 mice).
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mutations, had no significant effect on DMBA/TPA-induced
epidermal tumorigenesis (our unpublished data).
The formation of DMBA-induced dermal benign MGs and their
malignant progression to invasive human-melanoma-like MGs
upon keratinocyte-selective ablation of RXRa involves a
paracrine signalling(s).
In contrast to human skin melanocytes, which are mainly
located in the interadnexal epidermis, mouse skin melano-
cytes drastically decrease in interfollicular epidermis from the
fourth day after birth. In adult mice, few melanocytes are
present in the dermis, whereas the bulk of them are confined
to hair follicles (Hirobe, 1984; Hardy, 1992; Yoshida et al.,
1996). A single topical application of DMBA to mouse skin
induces the formation of benign MGs that become visible
as nevi (dermal accumulation of melanocytes) (Husain
et al., 1991). Our data show that nevi are increased in
number and size upon further RXRa ablation in epidermal
keratinocytes of adult mice. Importantly, and as expected,
RXRa ablation could not be detected in isolated MGs,
whereas it was readily revealed in MG-free epidermis. In
both CT and RXRaep/ mice, multiple TPA applications
further increase the number of nevi. Furthermore, irrespective
of TPA treatment, a significant proportion of MGs from
RXRaep/ mice exhibited a malignant progression to
invasive human-melanoma-like tumors. In agreement with
the report of Husain et al. (1991), this malignant progression
was never found in CT mice. Therefore, the genetically
DMBA-initiated proliferation of melanocytes and their
malignant progression must be controlled by paracrine/
juxtacrine signals, which emanate from keratinocytes, and
are regulated by RXRa.
The identity of the NR partner(s) which heterodimerize(s)
with RXRa in keratinocytes to directly or indirectly down-
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Figure 6. DMBA/TPA-induced epidermal tumors and MGs in VDR-null mice. (a) Dorsal view of CT (VDRþ /þ ) (left) and VDR-null (VDR/, right) mice
25 weeks after the start of DMBA/TPA treatment. Arrows point to papilloma-like epidermal tumors. (b) Formation of epidermal tumors in DMBA/TPA-treated
CT and VDR/ mice. Values are expressed as mean7SEM (n¼ 7 mice). (c) Length distribution of epidermal tumors in CT and VDR/ mice, 30 weeks
after the start of the DMBA/TPA treatment. Values are expressed as mean7SEM (n¼ 7 mice). (d) Size distribution of MGs in CT and VDR/ mice, 30 weeks
after the start of TPA treatment. Values are expressed as mean7SEM (n¼7 mice). (e, f) Hematoxylin- and eosin-stained paraffin sections (5 mm thick) of
(e) CT and (f) VDR/ MGs in skin biopsies taken after 25 weeks of DMBA/TPA treatment. Bar¼ 33mm. (g, h) Electron microscopic analysis of (g) CT and
(h) VDR/ MGs taken after 25 weeks of DMBA/TPA treatment. N, nucleus. Bar¼ 2.5mm.
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regulate the generation of nevi and their malignant progres-
sion to human-melanoma-like tumors is presently unknown.
No increase in DMBA-induced nevi formation and malignant
progression was found in skin of mice selectively ablated for
possible RXRa partners in keratinocytes (PPARb, PPARg,
RARa, RARg, RARb, RARa and g) or in the germ line (PPARa,
and LXRb) (this study and our unpublished results). Further-
more, VDR cannot be the partner of RXRa in heterodimers,
which in keratinocytes are instrumental in preventing the
overproduction of nevi (melanocytosis), even though we
found a marked increase in benign MGs in VDR-null
mutants, which however did not progress to malignancy.
Indeed, keratinocyte-selective-ablation of VDR did not
result in melanocytosis (our unpublished results). Thus,
our results strongly suggest that RXRa heterodimerized
in keratinocytes with as yet unidentified NR partner(s)
prevents the proliferation, migration and malignant progres-
sion of DMBA-initiated melanocytes through downregulation
of paracrine pathways.
Taken together our present study demonstrates that
keratinocytic RXRa plays a key role in modulating the
formation and malignant transformation of DMBA/TPA-
induced epidermal skin tumors, as well as in the generation
of DMBA-induced MGs and their malignant progression to
human-melanoma-like MGs. Several lines of evidence
support the conclusion that distinct RXRa/NR-mediated
mechanisms are involved upon DMBA/TPA treatment to
block (i) the generation of paracrine signal(s) that trigger(s) the
proliferation of melanocytes and their possible malignant
transformation, and cannot be prevented by FA co-treatment,
and (ii) the occurrence of cell-autonomous events that lead to
formation and malignant progression of epidermal tumors,
and can be prevented by FA co-treatment. First of all, the
tumor promoter TPA is indispensable to generate epidermal,
but not melanocytic tumors in adult RXRaep/ mice in which
RXRa is selectively ablated in epidermal keratinocytes.
Secondly, in DMBA/TPA-treated RXRaep/mice, the topical
application of the synthetic glucocorticoid FA strikingly
prevents the occurrence of epidermal tumors, but not the
generation of melanocytic tumors (MGs and human-like-
melanomas). Thirdly, in keratinocytes, RXRa/PPARg hetero-
dimers appear to mediate cell-autonomous suppressive
effects on epidermal tumorigenesis and malignant progres-
sion, whereas they do not play any role in preventing the
formation and malignant progression of MGs. Thus, through
its multiple NR partnerships, RXRa in keratinocytes plays a
paramount role in the control of chemically induced
tumorigenesis, not only in the epidermis, but also in
melanocytes. This emphasizes the crucial role of keratino-
cytes in skin tumorigenesis, and raises the possibility that they
could play a similar role in the generation of UV-induced
tumors, notably in the formation and malignant progression
of melanocytic tumors.
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